Novartis, Juno report updated CAR T data for DLBCL

In abstracts released ahead of next month's American Society of Hematology meeting, Novartis AG (NYSE:NVS; SIX:NOVN) and Juno Therapeutics Inc. (NASDAQ:JUNO) revealed data for their chimeric antigen receptor T cell therapies to treat relapsed or refractory diffuse large B cell lymphoma.

Novartis reported updated data from the pivotal Phase II JULIET trial of Kymriah tisagenlecleucel, and Juno from the Phase I TRANSCEND NHL 001 trial of JCAR017.

Among 81 evaluable patients receiving Kymriah

Read the full 710 word article

User Sign In